13F HOLDINGS REPORT
Athyrium Capital Management, LP
Quarter ended Q1 2023 · Filed February 14, 2023 · Accession 0001567619-23-002883
Total Value
$237.9M
Positions
11
Other Managers
0
Confidential Omitted
No
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Amryt Pharma PLC | 03217L106 | 8,857,268 | $64.7M | 27.18% |
| 2 | Biora Inc. | 74319FAB3 | 103,500,000 | $56.3M | 23.65% |
| 3 | Omeros Corp | OMER | 58,131,000 | $31.7M | 13.32% |
| 4 | Omeros Corp | OMER | 21,005,000 | $20.2M | 8.51% |
| 5 | RVL PHARMACEUTICALS PLC | G6S41R101 | 14,600,444 | $16.4M | 6.87% |
| 6 | CAREMAX INC | 14171W103 | 4,467,219 | $16.3M | 6.85% |
| 7 | Paratek Pharmaceuticals Inc. | 699374AB0 | 9,000,000 | $8.2M | 3.45% |
| 8 | BridgeBio Pharma Inc. | BBIO | 20,000,000 | $7.8M | 3.26% |
| 9 | PUMA BIOTECHNOLOGY INC | PBYI | 1,792,114 | $7.6M | 3.19% |
| 10 | Biora Inc. | 74319F107 | 42,362,097 | $5.6M | 2.34% |
| 11 | Societal CDMO Inc. | 75629F109 | 2,202,420 | $3.3M | 1.38% |